Compare BBSI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | ARQT |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.2M | 2.9B |
| IPO Year | 1994 | 2020 |
| Metric | BBSI | ARQT |
|---|---|---|
| Price | $37.76 | $26.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $42.67 | $34.00 |
| AVG Volume (30 Days) | 241.1K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | 5.05 | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $920,432,000.00 | $376,072,000.00 |
| Revenue This Year | $6.59 | $34.85 |
| Revenue Next Year | $6.05 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.50 | ★ 91.34 |
| 52 Week Low | $25.33 | $13.06 |
| 52 Week High | $49.65 | $31.77 |
| Indicator | BBSI | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 60.46 |
| Support Level | $35.95 | $24.81 |
| Resistance Level | $40.02 | $27.26 |
| Average True Range (ATR) | 1.41 | 1.22 |
| MACD | 0.29 | 0.05 |
| Stochastic Oscillator | 99.17 | 57.50 |
Barrett Business Services Inc is a provider of business management solutions for small and mid-sized companies through a platform that combines management consulting expertise with human resource tools to help business owners manage and operate their businesses more effectively. The company has two categories of services: Professional Employer Services (PEO) and Staffing. The majority of revenue is derived from the Professional Employer Services segment, which provides clients with human resource advisory services, HRIS access, retirement plans, a learning management system, and a web-based technology platform, myBBSI.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.